Cash Position
The latest news about Cash Position: headlines, AI summaries and the full story from every source.
- Artelo Biosciences Reports Third Quarter GAAP EPS of -$3.19
- Kyverna Therapeutics Reports Q3 GAAP EPS of -$0.68, Slightly Beating Estimates
- ERock, Inc. Reports Q3 GAAP EPS Miss of $0.29
- Altimmune Reports Q3 GAAP EPS of -$0.15, Missing Estimates by $0.02
- Cardiff Oncology Reports Q3 Earnings Beat on Revenue and EPS
- Absci Reports Q3 Results: Revenue Misses Estimates Amid Declining Year-over-Year Growth
- Pharvaris Reports Third Quarter Financial Results and Clinical Updates
- Vista Gold Reports Q3 GAAP EPS of -$0.05 and Increased Cash Reserves
- DarioHealth Reports Q3 Earnings Beat with Improved Profitability and Revenue Growth
- Westwater Resources Reports Improved Q3 Results and Receives $25 Million EXIM Loan Approval
- T1 Energy Reports Q3 Earnings Miss and Updates FY26 Outlook
- Xanadu Reports Q3 2026 Financial Results and Technical Hardware Milestones
- Faraday Copper Reports Q3 GAAP Earnings Per Share of -C$0.03
- Vivani Medical Reports Q3 GAAP EPS of -$0.08, Exceeding Analyst Expectations
- MiNK Therapeutics Reports Third Quarter Financial Results Exceeding Estimates
- PolyPid Reports Third Quarter Financial Results
- Palisade Bio Reports Q3 GAAP EPS of -$0.07, Missing Estimates
- Hyliion Holdings (HYLN) Shares Rise After Q3 Earnings Beat Revenue and EPS Estimates
- Hyliion Holdings Reports Q3 Earnings Beat with Significant Revenue Growth
- Intelligent Bio Solutions Reports Q1 Revenue of $1.39 Million and Improved Gross Margins
- AST SpaceMobile Reports Q3 2026 Revenue of $42.3 Million and Provides Full-Year Guidance
- Rio2 Limited Reports Q3 2026 Non-GAAP EPS of $0.04 and Revenue of $115.38 Million
- CalciMedica Reports Third Quarter GAAP EPS of -$0.24, Exceeding Estimates
- Upstream Bio Reports Third Quarter Financial Results
- PMV Pharmaceuticals Reports Q3 GAAP EPS of -$0.52, Missing Estimates by $0.18
- KULR Technology Reports Q3 Revenue Growth of 197% and Positive GAAP EPS
- Scholar Rock Reports Q3 2026 Third Quarter Results Exceeding Estimates
- 908 Devices Reports Q3 Revenue Growth and Earnings Beat
- Maze Therapeutics Reports Q3 2026 GAAP EPS of -$0.79 and Increased Net Loss
- Surrozen Reports Q3 GAAP EPS Miss of $9.92
- Senseonics Reports Q3 Revenue Growth of 142% and EPS Beat
- Mind Medicine Reports Q3 GAAP EPS of -$0.46, Exceeding Analyst Expectations
- Bicara Therapeutics Reports Q3 GAAP EPS Miss Amid Increasing Cash Reserves
- Praxis Precision Medicines Reports Q3 Non-GAAP EPS Beat
- bioAffinity Technologies Reports Q3 Revenue of $1.1 Million and GAAP EPS of -$5.89
- Karnalyte Resources Reports Q3 GAAP EPS of -$0.01
- TEN Holdings Reports Q3 Revenue Growth to $0.64 Million Amid GAAP Net Loss
- Elutia Reports Q3 2026 Revenue Growth Driven by Cardiovascular Segment
- Vogenx, Inc. Reports Q3 GAAP EPS of -$0.47, Missing Estimates by $0.40
- Elicio Therapeutics Reports Narrowed Net Loss for Third Quarter
- Janux Therapeutics Reports Q3 Earnings Beat with $9.29 Million in Revenue
- INmune Bio Reports Q3 GAAP EPS of -$0.17, Missing Estimates by $0.02
- Verastem Reports Q3 2026 Financial Results with Earnings and Revenue Miss
- 10x Genomics Reports Q3 Earnings with Revenue and EPS Beats
- Natera Reports Q3 Revenue Beat Amid GAAP EPS Miss
- Corvus Pharmaceuticals Reports Q3 GAAP EPS Miss Amid Significant Cash Increase
- Zai Lab Reports Q3 2026 Financial Results and Clinical Progress
- Agios Reports Q3 2026 Revenue Surge Driven by Thalassemia Product Launch
- Korro Bio Reports Q3 GAAP EPS of -$0.98, Exceeding Analyst Expectations
- Palvella Therapeutics Reports Q3 GAAP EPS of -$1.70, Exceeding Estimates